BTK inhibitor has promising safety and efficacy profiles in relapsed CLL treatment
WEEKLY MOST-READ RANKING
#01Introduce standard working hours for HA doctors, says lawmaker
#02Product Highlight - Sovaldi
#03Original New Drug Application Approvals by US FDA (1 – 15 Dec 2015)
#04Poor cardiovascular health predicts cardiovascular disease and cancer risk in minorities and less educated postmenopausal women
#05US FDA approves MSD’s new HCV drug
In combination w/ other medicinal products for the treatment of chroni...
Treatment of relapsing remitting multiple sclerosis in adults.